DSM Capital Partners LLC Has $172.68 Million Position in Novo Nordisk A/S (NYSE:NVO)

DSM Capital Partners LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 16.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,007,412 shares of the company's stock after acquiring an additional 286,912 shares during the period. Novo Nordisk A/S accounts for 2.7% of DSM Capital Partners LLC's portfolio, making the stock its 11th biggest holding. DSM Capital Partners LLC's holdings in Novo Nordisk A/S were worth $172,678,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of NVO. Center for Financial Planning Inc. lifted its holdings in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Daiwa Securities Group Inc. acquired a new stake in Novo Nordisk A/S in the third quarter worth about $28,000. Capital Performance Advisors LLP acquired a new stake in Novo Nordisk A/S in the third quarter worth about $42,000. Albion Financial Group UT lifted its holdings in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after purchasing an additional 278 shares during the period. Finally, Sound Income Strategies LLC lifted its holdings in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock worth $46,000 after purchasing an additional 243 shares during the period. Institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on NVO shares. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Sunday, December 29th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Trading Up 5.2 %

NYSE NVO traded up $4.33 on Friday, hitting $88.07. 15,117,993 shares of the company were exchanged, compared to its average volume of 9,263,626. The firm has a market capitalization of $395.19 billion, a P/E ratio of 26.77, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $77.82 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company's 50 day moving average price is $86.01 and its 200-day moving average price is $108.22.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S's dividend payout ratio is currently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.